Composition, form of production and packaging
A solution for intravesical administration in the form of a transparent or slightly colored liquid.
1 l
hydroxymethylquinoxaline dioxide 1 g
Excipients: glycine 15 g, water d / and up to 1 l.
250 ml - polymer containers (25) - cardboard boxes.
500 ml - polymer containers (15) - cardboard boxes.
3 l - containers (3) of low density polyethylene - boxes made of cardboard.
5 l - containers (2) from low density polyethylene - boxes made of cardboard.
10 l - containers (1) of low density polyethylene - boxes made of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2014.
PHARMACHOLOGIC EFFECT
Urotravenol contains in its composition hydroxymethylquinoxaline dioxide having a broad spectrum of antibacterial action. It is active against Proteus vulgaris, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Salmonella spp, Staphylococcus spp., Streptococcus spp., Pathogenic anaerobes (Clostridium perfringens). It acts on strains of bacteria resistant to other antimicrobial medicines, including antibiotics. Does not have a local irritant effect. Possible development of drug resistance of bacteria. The use of Urotravenol in endoscopic interventions reduces the likelihood of complications of infectious etiology.
Presence in the composition of glycine provides isoosmoticity of Urotravenol and thus prevents cellular damage to tissues during prolonged contact with the drug, which excludes the occurrence of the syndrome of "water intoxication" as a postoperative complication.
Glycine, when dissolved, forms zwitter ions, which practically do not increase the electrical conductivity of the solution, and hydroxymethylquinoxaline dioxide is not an electrolyte. As a result, Urotravenol is electrically non-conductive, which makes it possible to use power tools when it is used to irrigate or fill cavities during endoscopic interventions.
INDICATIONS
- for filling and continuous washing of the bladder cavity during diagnostic and operative endoscopic interventions;
- with transurethral resections (TUR) of prostatic hyperplasia;
- Irrigation (washing) of the bladder in the postoperative period;
- with diagnostic and therapeutic cystoscopy to fill the cavity of the bladder.
DOSING MODE
Urotavenol is used to enter the bladder cavity with endoscopic interventions. At the same time, the degree of filling of the cavity necessary for performing the manipulations is reached and it is possible to continuously wash it. The drug consumption ranges from 10 to 30 liters (TUR). The drug can be used for postoperative irrigation of the bladder, as well as for diagnostic and therapeutic cystoscopy.
Polymeric containers with a capacity of 0.25 L and 0.5 L are used to fill the bladder cavity with cystoscopy, endoscopic manipulations, 3 L capacity for postoperative irrigation of the bladder, 5.0 L capacity and 10.0 L capacity for TUR.
SIDE EFFECT
Renal failure. When the drug is used, allergic reactions, headache, chills, fever, dyspeptic disorders, muscle cramps, photosensitizing effect (the appearance of pigment spots on the body when exposed to sunlight), near-dermatitis can occur.
CONTRAINDICATIONS
- hypersensitivity to the drug or its components;
- adrenal insufficiency (including in the anamnesis);
- pregnancy, lactation;
- age to 18 years.
PREGNANCY AND LACTATION
Contraindicated in pregnancy and lactation.
APPLICATION FOR CHILDREN
Contraindicated for children under 18 years.
OVERDOSE
Symptoms: dystrophy, acute adrenal insufficiency.
Treatment: symptomatic, it is necessary to control the concentration of glucose in the blood.
DRUG INTERACTION
Studies on interactions with other drugs have not been conducted.
TERMS OF RELEASE FROM PHARMACY
For hospitals.
TERMS AND CONDITIONS OF STORAGE
At a temperature of 10 В° C to 25 В° C. Keep out of reach of children. Shelf life - 1 year.
